{"product_id":"residual-risks-and-evolving-atherosclerotic-plaques-what-patients-need-to-know","title":"Residual Risks and Evolving Atherosclerotic Plaques: What Patients Need to Know","description":"\u003cp\u003eAtherosclerosis—the buildup of fatty plaque inside artery walls—remains the world's leading cause of death and disability, even after decades of medical advances. This research review highlights a crucial problem: despite statins, advanced surgical techniques, and better control of risk factors like smoking, many patients still face a \"residual risk\" of heart attacks and strokes. The authors explain how new imaging tools are transforming our understanding of plaque formation and stability, potentially paving the way for better prediction and prevention of life-threatening cardiovascular events.\u003c\/p\u003e\n\n\u003ch1\u003eResidual Risks and Evolving Atherosclerotic Plaques: What Patients Need to Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#atherosclerosis\"\u003eUnderstanding Atherosclerosis: The Basics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#residual-risk\"\u003eThe Problem of Residual Risk\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow Researchers Study Plaques: New Imaging Methods\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What We Now Know About Plaque Evolution\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAtherosclerosis is the world's leading cause of death and disability, affecting coronary and carotid arteries.\u003c\/li\u003e\n\u003cli\u003eResidual risk means heart attacks and strokes still occur despite optimal treatment with statins, surgery, and lifestyle changes.\u003c\/li\u003e\n\u003cli\u003eAdvanced imaging (IVUS, OCT, NIRS) can reveal plaque composition, lipid volume, and fibrous cap thickness inside artery walls.\u003c\/li\u003e\n\u003cli\u003eDangerous plaques have a thin fibrous cap, large fatty core, and inflammation; they can evolve from stable to unstable over time.\u003c\/li\u003e\n\u003cli\u003ePatients can shift plaques toward stability by taking statins as prescribed, quitting smoking, exercising, and controlling blood pressure and blood sugar.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eHeart disease and stroke remain the world's biggest killers. This review article, published in the journal \u003cem\u003eMolecular and Cellular Biochemistry\u003c\/em\u003e, tackles a question that has puzzled cardiologists for years: \u003cstrong\u003eWhy do some patients still experience heart attacks and strokes even when they receive the best available treatment?\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eResearchers Sunil K. Noothi, Mohamed Radwan Ahmed, and Devendra K. Agrawal from the Department of Translational Research at Western University of Health Sciences in Pomona, California, set out to examine this persistent problem. Their goal was to explain the gap between current treatments and perfect outcomes—what doctors call \u003cstrong\u003e\"residual risk.\"\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe authors highlight that atherosclerotic disease (hardening and narrowing of the arteries) of the coronary arteries (which supply blood to the heart) and carotid arteries (which supply blood to the brain) is the \u003cstrong\u003eprimary global cause of significant mortality and morbidity\u003c\/strong\u003e. This means it is the number one reason people around the world die or become seriously ill.\u003c\/p\u003e\n\n\u003cp\u003eChronic occlusive diseases—conditions where arteries become progressively blocked over time—have fundamentally changed the health landscape. This shift affects not just wealthy nations but also developing countries, where cardiovascular disease has become an increasingly heavy burden alongside traditional infectious diseases.\u003c\/p\u003e\n\n\u003ch2 id=\"atherosclerosis\"\u003eUnderstanding Atherosclerosis: The Basics\u003c\/h2\u003e\n\n\u003cp\u003eAtherosclerosis is a slow, progressive condition in which plaque—a combination of cholesterol, fat, calcium, and inflammatory cells—accumulates inside artery walls. Think of it like rust building up inside a pipe: over time, the opening narrows, and blood flow becomes restricted.\u003c\/p\u003e\n\n\u003cp\u003eBut the story is more complicated than simple narrowing. Over the past two decades, researchers have learned that \u003cstrong\u003eplaque composition matters more than plaque size\u003c\/strong\u003e. Some plaques are stable—they sit quietly in the artery wall for years without causing trouble. Others are unstable or \"vulnerable\"—they have thin fibrous caps (the protective covering over the fatty core) that can rupture, triggering a blood clot that blocks the artery entirely.\u003c\/p\u003e\n\n\u003cp\u003eWhen such a rupture happens in a coronary artery, the result is a heart attack (sometimes called an acute cardiac event). When it happens in a carotid artery, it can cause a stroke. These are what the authors call \u003cstrong\u003emajor adverse atherothrombotic events\u003c\/strong\u003e—the catastrophic outcomes that doctors are working desperately to prevent.\u003c\/p\u003e\n\n\u003ch2 id=\"residual-risk\"\u003eThe Problem of Residual Risk\u003c\/h2\u003e\n\n\u003cp\u003eOver the last four decades, medicine has made enormous progress. The authors acknowledge several key advances:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdvanced revascularization techniques\u003c\/strong\u003e—procedures like coronary bypass surgery and stent placement that physically reopen blocked arteries\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWidespread use of statins\u003c\/strong\u003e—medications that lower cholesterol and reduce inflammation\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSuccessful targeting of modifiable risk factors\u003c\/strong\u003e—particularly smoking cessation and increased exercise\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite all these achievements, the authors point to a sobering reality: \u003cstrong\u003ethere is still a definite \"residual risk\" in the population.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eEvery year, many prevalent cases (people living with the disease) and new cases (people newly diagnosed) continue to appear. This persistent risk exists even in patients who take their medications faithfully, adopt healthy lifestyles, and receive state-of-the-art procedures. The residual risk is the gap between what current treatments can achieve and what would be needed to fully eliminate heart attacks and strokes.\u003c\/p\u003e\n\n\u003cp\u003eThis review places special emphasis on \u003cstrong\u003estrokes and cardiovascular risks\u003c\/strong\u003e, noting that both conditions share the same underlying disease process. If doctors can better understand why plaques evolve and rupture, they might be able to close this gap.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow Researchers Study Plaques: New Imaging Methods\u003c\/h2\u003e\n\n\u003cp\u003eOne of the most exciting developments described in this review is the use of advanced imaging technology to look inside arteries. Previously, doctors relied on \u003cstrong\u003econventional angiography\u003c\/strong\u003e—an X-ray technique that shows only the silhouette of the artery lumen (the hollow opening where blood flows). While useful for detecting blockages, angiography cannot reveal what is happening inside the artery wall itself.\u003c\/p\u003e\n\n\u003cp\u003eThree newer techniques are changing that picture:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntravascular ultrasound (IVUS)\u003c\/strong\u003e—a tiny ultrasound probe mounted on a catheter (a thin flexible tube) that is threaded into the artery. It uses sound waves to create detailed images of the artery wall from the inside, revealing the size and extent of plaque that angiography cannot see.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOptical coherence tomography (OCT)\u003c\/strong\u003e—a catheter-based imaging method that uses near-infrared light to produce extremely high-resolution images. OCT provides exceptionally detailed views of the plaque surface, allowing doctors to measure the thickness of the fibrous cap that protects the plaque's fatty core.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNear-infrared spectroscopy (NIRS)\u003c\/strong\u003e—a technique that shines near-infrared light onto the artery wall and analyzes the reflected spectrum to identify the chemical composition of the plaque. NIRS can detect lipid (fat) content, helping to identify dangerous lipid-rich plaques.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors explain that these techniques are being used in clinical settings to achieve \u003cstrong\u003esurrogate end points\u003c\/strong\u003e—measurable markers that stand in for, and help predict, real patient outcomes like heart attacks and strokes. Since major cardiovascular events are relatively rare in a short time frame, researchers use these imaging markers (such as changes in plaque size or composition) to evaluate how well a treatment is working.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What We Now Know About Plaque Evolution\u003c\/h2\u003e\n\n\u003cp\u003eThe review presents a critical discussion of how atherosclerotic plaques evolve in both coronary and carotid arteries. This new understanding has fundamentally changed the scientific community's view of plaque biology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eChanging views on stable vs. unstable plaques\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eTraditionally, doctors classified plaques as either stable (safe) or unstable (dangerous). The authors explain that this binary view is too simple. Plaques exist on a spectrum and can change over time. A plaque that appears stable today may evolve into a destabilized, high-risk plaque tomorrow—and vice versa. This concept of \u003cstrong\u003eevolving plaques\u003c\/strong\u003e is central to the review.\u003c\/p\u003e\n\n\u003cp\u003eThe key features that make a plaque dangerous include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eA thin fibrous cap (the protective layer becomes weakened)\u003c\/li\u003e\n  \u003cli\u003eA large lipid (fatty) core\u003c\/li\u003e\n  \u003cli\u003eActive inflammation within the plaque (inflammatory cells infiltrating the tissue)\u003c\/li\u003e\n  \u003cli\u003eA tendency toward vulnerability—meaning the plaque is prone to rupture\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePlaque evolution before a major event\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003ePerhaps the most important insight highlighted by the authors is that plaques do not suddenly rupture without warning. They evolve over time, passing through stages of stability and instability before a major adverse atherothrombotic event occurs. Understanding this evolution is critical because it means there may be a window of opportunity to intervene before a heart attack or stroke happens.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat new imaging reveals\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe advanced techniques described above are now providing \"exquisite information\" that was previously impossible to obtain with conventional angiography. Specifically, doctors can now assess:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque size\u003c\/strong\u003e—how much of the artery wall is occupied by plaque\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque composition\u003c\/strong\u003e—what the plaque is made of (fat, calcium, fibrous tissue, or a mixture)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipid volume\u003c\/strong\u003e—the amount of fatty material within the plaque, which correlates with danger\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFibrous cap thickness\u003c\/strong\u003e—the strength of the protective barrier over the fatty core; thinner caps are more likely to rupture\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAll of these features serve as surrogate end points that help researchers and clinicians identify the most dangerous plaques and monitor how they change over time or in response to treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis research has several direct implications for patients living with—or at risk for—atherosclerotic disease.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBetter risk identification\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe ability to see plaque composition and fibrous cap thickness means that doctors can potentially identify \"vulnerable\" plaques before they rupture. Rather than simply asking \"how blocked is the artery?\" they can now ask \"how dangerous is the plaque?\" This is a crucial distinction, because many heart attacks occur at sites with only moderate narrowing—the danger comes from the plaque's vulnerability, not its size.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePersonalized treatment potential\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eIf a patient is found to have a lipid-rich plaque with a thin fibrous cap, they may benefit from more aggressive cholesterol-lowering therapy or additional anti-inflammatory treatment. Conversely, a patient with a thick-capped, stable plaque might be safely managed with standard care. This moves medicine closer to personalized treatment plans based on each individual's actual plaque profile.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe ongoing challenge of residual risk\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eFor patients, the concept of residual risk serves as an important reminder: even the best medical care cannot eliminate all danger. The authors note that this risk persists \"despite advanced management settings,\" meaning that patients and doctors must remain vigilant even after successful procedures and optimal medical therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInflammation as a key player\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe review highlights inflammation as a central mechanism in plaque evolution. This suggests that future treatments may need to address inflammation directly, not just cholesterol levels. Some anti-inflammatory medications have already been shown to reduce cardiovascular events in clinical trials, and this area of research continues to evolve.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Research\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand what this review does and does not show. Like all scientific studies, this work has limitations that patients should be aware of:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThis is a review article, not a clinical trial.\u003c\/strong\u003e It summarizes and interprets existing research rather than presenting new patient data. As such, it cannot prove that any specific treatment changes outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurrogate end points are not the same as patient outcomes.\u003c\/strong\u003e While changes in plaque size, lipid volume, and fibrous cap thickness are strongly associated with cardiovascular risk, these imaging markers are not guaranteed to predict whether an individual patient will actually have a heart attack or stroke.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe imaging techniques described are not universally available.\u003c\/strong\u003e IVUS, OCT, and NIRS are performed in specialized centers and are not part of routine care for all patients with atherosclerosis. They are primarily used in research settings and high-risk cases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe article focuses on coronary and carotid arteries.\u003c\/strong\u003e The findings may not apply equally to atherosclerosis in other parts of the body, such as the peripheral arteries in the legs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients should understand that while these findings are promising, they represent an evolving area of science. More research is needed to determine how best to use this new information to improve survival and quality of life.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the insights from this review, here are practical steps patients can consider. These recommendations align with the \"modifiable risk factors\" the authors emphasize—things you can actively change:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTake your statin medication exactly as prescribed.\u003c\/strong\u003e Statins do more than lower cholesterol—they also stabilize plaques, making the fibrous cap thicker and reducing inflammation. Even if your cholesterol numbers look good, the plaque-stabilizing benefits continue.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuit smoking, and if you don't smoke, don't start.\u003c\/strong\u003e Smoking damages the endothelium (the lining of arteries), accelerates plaque growth, and promotes inflammation. It is one of the most powerful modifiable risk factors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExercise regularly.\u003c\/strong\u003e Even moderate physical activity improves blood flow, reduces inflammation, and helps stabilize blood pressure and weight. The authors specifically note exercise as a key modifiable factor that has successfully reduced risk over the past four decades.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eControl blood pressure and blood sugar.\u003c\/strong\u003e Hypertension and diabetes are major contributors to plaque progression. Work with your healthcare team to keep these in target ranges.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your medications.\u003c\/strong\u003e If you have multiple medications, including antiplatelet drugs (like aspirin or clopidogrel) and blood pressure medicines, take them consistently. The \"residual risk\" concept reminds us that every protective measure counts.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHave an open conversation with your cardiologist.\u003c\/strong\u003e Ask about your individual risk profile. In certain high-risk situations, newer imaging techniques might help clarify your condition, though they are not appropriate for everyone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed but not alarmed.\u003c\/strong\u003e The concept of evolving plaques means the disease is dynamic. A healthy lifestyle and proper medication can shift plaques toward stability. Your daily choices genuinely influence the character of the plaque inside your arteries.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors' emphasis on changing plaque biology offers a message of hope: \u003cstrong\u003ethe disease process is not static, and neither is the treatment strategy.\u003c\/strong\u003e Science is moving toward an era where doctors can not only detect blockages but also assess their biological danger and potentially intervene before a catastrophic event occurs.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the difference between a stable and a vulnerable (unstable) plaque?\u003c\/h3\u003e\n\u003cp\u003eA stable plaque sits quietly in the artery wall for years without causing trouble. A vulnerable plaque has a thin protective cap, a large fatty core, and active inflammation, making it prone to rupture. Rupture can trigger a blood clot that blocks the artery, causing a heart attack or stroke.\u003c\/p\u003e\n\u003ch3\u003eHow can doctors see plaque inside the artery wall instead of just the narrowing?\u003c\/h3\u003e\n\u003cp\u003eNew imaging tools such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near-infrared spectroscopy (NIRS) look inside the artery wall. IVUS uses sound waves, OCT uses light for high-resolution images, and NIRS detects fat content. These methods reveal plaque size, composition, and fibrous cap thickness, which standard angiography cannot.\u003c\/p\u003e\n\u003ch3\u003eWhat exactly makes a plaque dangerous?\u003c\/h3\u003e\n\u003cp\u003eA plaque is dangerous when it has a thin fibrous cap over a large lipid (fatty) core, along with active inflammation inside the plaque. This makes it vulnerable to rupture. Rupture can lead to a blood clot that blocks blood flow, causing a heart attack or stroke.\u003c\/p\u003e\n\u003ch3\u003eCan my plaque become less dangerous over time?\u003c\/h3\u003e\n\u003cp\u003eYes. Plaques are not fixed – they evolve on a spectrum between stable and unstable. Taking statins as prescribed, quitting smoking, exercising, and controlling blood pressure and blood sugar can shift plaques toward stability. Statins also thicken the fibrous cap and reduce inflammation, helping to make plaques safer.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my cardiologist about my personal risk and plaque vulnerability?\u003c\/h3\u003e\n\u003cp\u003eAsk about your individual risk profile, whether your plaque burden or composition is being assessed, and if newer imaging methods like IVUS, OCT, or NIRS are appropriate in your case. Also ask how aggressively to manage cholesterol, blood pressure, and inflammation, and whether all your medications are optimized to reduce residual risk.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion if my cardiologist says my plaque is stable but I still worry about residual risk of heart attack or stroke?\u003c\/h3\u003e\n\u003cp\u003eYes, a second opinion can be valuable if you have residual risk despite optimal treatment, because plaque vulnerability—not just narrowing—determines danger. Advanced imaging like IVUS, OCT, or NIRS can reveal fibrous cap thickness and lipid volume, which may change your risk assessment and treatment plan. If your doctor hasn't discussed these options, another expert might. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article:\u003c\/strong\u003e \"Residual risks and evolving atherosclerotic plaques\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Sunil K. Noothi, Mohamed Radwan Ahmed, Devendra K. Agrawal\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliation:\u003c\/strong\u003e Department of Translational Research, Western University of Health Sciences, Pomona, California, USA\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e \u003cem\u003eMolecular and Cellular Biochemistry\u003c\/em\u003e, published online March 10, 2023\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e DOI: 10.1007\/s11010-023-04689-0 | PMID: 36897542\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeywords from original article:\u003c\/strong\u003e Acute cardiac event; Atherosclerosis; Fibrous cap; Inflammation; Residual risk; Stable plaque; Unstable plaque; Vulnerability\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider regarding your specific condition and treatment options. This article was written for patients and caregivers to help bridge the gap between complex scientific literature and everyday understanding.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47459197878428,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.jp\/products\/residual-risks-and-evolving-atherosclerotic-plaques-what-patients-need-to-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}